Genmab Announces Financial Results for the First Nine

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genmab Announces Financial Results for the First Nine Months of 2016 and Improves 2016 Financial Guidance

November 2, 2016; Copenhagen, Denmark;

Interim Report for First Nine Months Ended September 30, 2016

Highlights

  • Net Sales of DARZALEX ® (daratumumab) by Janssen for the first nine months of 2016 were USD 372 million, resulting in royalty income of USD 45 million (DKK 298 million)
  • Announced U.S. and European regulatory submissions for daratumumab in relapsed or refractory multiple myeloma, triggering USD 25 million in milestone payments
  • Daratumumab received second Breakthrough Therapy Designation from U.S. Food and Drug Administration (FDA)
  • Announced FDA approval of Arzerra ® (ofatumumab) in combination with fludarabine and cyclophosphamide for relapsed chronic lymphocytic leukemia (CLL)
  • Entered commercial license agreement with Gilead Sciences for DuoBody ® Technology
  • 2016 financial guidance improved

“Throughout the third quarter we continued to see excellent progress in our DARZALEX program with Janssen.  Regulatory applications to expand the label for daratumumab to include relapsed or refractory multiple myeloma were submitted in the U.S. and Europe, triggering USD 25 million in milestone payments.  Daratumumab also received its second Breakthrough Therapy Designation from the FDA.  We continued to see progress with Arzerra too, with another CLL indication approved in the U.S., and we made progress with our DuoBody technology, with a new commercial agreement with Gilead Sciences,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Financial Performance First Nine Months of 2016

  • Revenue was DKK 889 million in the first nine months of 2016 compared to DKK 558 million in the first nine months of 2015. The increase of DKK 331 million, or 59%, was mainly driven by higher royalty and milestone revenue under our daratumumab collaboration with Janssen.
  • Operating expenses were DKK 544 million in the first nine months of 2016 compared to DKK 380 million in the first nine months of 2015. The increase of DKK 164 million, or 43%, was due to the additional investment in our pipeline of products, including the advancement of tisotumab vedotin, HuMax ® -AXL-ADC, HexaBody ® -DR5/DR5, DuoBody-CD3xCD20, and our other pre-clinical programs.
  • Operating income was DKK 345 million in the first nine months of 2016 compared to DKK 355 million in the first nine months of 2015.  The decrease of DKK 10 million, or 3%, was driven by the one-time reversal of the ofatumumab funding liability of DKK 176 million in 2015, combined with increased operating expenses in 2016, which were partly offset by higher revenue in 2016.
  • On September 30, 2016, Genmab had a cash position of DKK 3,942 million compared to DKK 3,493 million at December 31, 2015. This represented a net increase of DKK 449 million, which was driven primarily by income from operations and the proceeds from the exercise of warrants of DKK 184 million, partially offset by the purchase of treasury shares for DKK 118 million.

Business Progress Third Quarter

Daratumumab

  • August: Regulatory submission in Europe for daratumumab (DARZALEX) in patients with multiple myeloma who have received at least one prior therapy. In addition, a regulatory application was submitted in the U.S. for the use of daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who received at least one prior therapy. The submissions triggered milestone payments of USD 10 million, and USD 15 million, respectively, to Genmab.
  • July: The FDA granted Breakthrough Therapy Designation for DARZALEX injection in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Ofatumumab

  • August: The FDA approved ofatumumab (Arzerra) in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with relapsed CLL.

DuoBody

  • August: Entered an agreement to grant Gilead Sciences, Inc. an exclusive license and an option on a second exclusive license, to use the DuoBody technology platform to create and develop bispecific antibody candidates for a therapeutic program targeting HIV. Under the terms of the agreement, Genmab received an upfront payment of USD 5 million from Gilead Sciences.

Subsequent Event

  • October: The FDA granted Priority Review for the use of daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of February 17, 2017 to take a decision on daratumumab in this indication. In addition, the FDA granted a Standard Review period for the use of daratumumab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received at least two prior therapies, including a proteasome inhibitor (PI) and an immunomodulatory agent. The PDUFA date for the combination of daratumumab with pomalidomide/dexamethasone is June 17, 2017.

Outlook

Genmab is improving its 2016 financial guidance published on August 9, 2016 due to increased royalty and milestone income related to the sales of DARZALEX resulting in increased operating income and cash position.

MDKK Revised Guidance Previous Guidance
Revenue 1,200 – 1,250 975 – 1,025
Operating expenses (800) – (850) (800) – (850)
Operating income 375 – 425 150 – 200
Cash position at end of year* 3,650 – 3,750 3,550 – 3,650
*Cash, cash equivalents, and marketable securities

Conference Call

Genmab will hold a conference call in English to discuss the results for the first nine months of 2016 today, Wednesday, November 2, at 6.00 pm CET, 5.00 pm GMT or 1.00 pm EDT. The dial in numbers are:

+1 212 444 0895 (US participants) and ask for the Genmab conference call +44 20 3427 0503 (international participants) and ask for the Genmab conference call

A live and archived webcast of the call and relevant slides will be available at www.genmab.com .

Contact:         

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

The interim report contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section “Risk Management” in Genmab’s annual report, which is available on www.genmab.com and the “Significant Risks and Uncertainties” section in the interim report. Genmab does not undertake any obligation to update or revise forward looking statements in the interim report nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo ® ; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody ® and UniBody ® . Arzerra ® is a trademark of Novartis AG or its affiliates. DARZALEX ® is a trademark of Janssen Biotech, Inc.

Download the full Interim Report for the first nine months of 2016 on attachment or at www.genmab.com .

CVR no. 2102 3884

Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 96

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
Investors, Portillo's Fraud Claims Demand Your Attention

Updated Category News Views 91

Portillo's Investors Caught in a Tough Spot Ah, Portillo's. You thought those hot dogs were the only spicy thing you're biting into? Try these allegations on for size. Investors are biting back with a securities fraud lawsuit, and the details are saltier than a bucket of fries. The folks who held PTLO shares between September 19, 2023, and May 4, 2026, are in the...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 137

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 149

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 207

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 110

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Ave7® Pioneers AI-Driven Marketplace Evolution

Updated Category News Views 99

AI Reshapes the Agency Paradigm Nobody saw this coming a decade ago, but here we are—AI's taking the wheel, but with humans still riding shotgun. The agency world, particularly the one dealing with e-commerce giants like Amazon, Walmart, and Target, has flipped on its head. Ave7® steps up as the frontrunner, adapting faster than a broker's reflex after a market bell....

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 66

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 48

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading

Top 5 Most Recently Viewed Articles

Vancity Achieves Remarkable Q2 Performance Amid Strategic Shift

Updated Category News Views 345

Vancity Reports Strong Financial Performance in Q2 Vancity recently showcased its outstanding financial results for the second quarter, demonstrating impressive growth across various metrics and solidifying its commitment to its members. This performance is part of Vancity's transformative vision to enhance member experience while making significant contributions to local...

Continue Reading
Celebrating Courtney Rollings Latham's Exceptional Contributions

Updated Category News Views 283

Honoring Courtney Rollings Latham, M.Ed, BCBA It brings us great joy to acknowledge Courtney Rollings Latham, M.Ed, BCBA, for achieving the status of a Pinnacle Professional Member in The Inner Circle of Excellence. This recognition showcases her steadfast commitment to enhancing the fields of Behavior Analysis and Special Education. A Passionate Educator and Analyst...

Continue Reading
Savers Value Village, Inc. Reveals Sales Growth and Conference Plans

Updated Category News Views 158

Savers Value Village, Inc. Reports Preliminary Sales Results BELLEVUE, Wash. – Savers Value Village, Inc. (NYSE: SVV) has released its preliminary net sales for the recent quarter along with its full year results for fiscal 2024. This announcement coincides with the Company’s upcoming participation in the ICR Conference scheduled for mid-January 2025. Sales...

Continue Reading
Empowering Salon Professionals Through Natural Disasters Support

Updated Category News Views 241

Empowering Professionals in the Face of Adversity Natural disasters can strike unexpectedly, causing chaos and distress. My Salon Suite®, a franchise dedicated to providing beauty, health, and wellness professionals with personal spaces for their businesses, has been at the forefront of community support during such challenging times. As we navigate through the hurricane...

Continue Reading
Major Revenue Surge: POP Culture Group's Impressive FY2025 Results

Updated Category News Views 201

POP Culture Group Achieves Record Revenue in FY2025 In a remarkable financial breakthrough, POP Culture Group Co., Ltd. (Nasdaq: CPOP) has announced its fiscal year 2025 results, showcasing an incredible revenue surge that exceeded $100 million for the first time. This milestone represents a significant leap, with revenue increasing by 127% compared to the previous fiscal...

Continue Reading